NCT04178577View on ClinicalTrials.gov

Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function

PHASE1CompletedINTERVENTIONAL

Enrollment

39

Participants

Timeline

Start Date

December 6, 2019

Primary Completion Date

September 6, 2020

Study Completion Date

September 11, 2020

Conditions

Renal Impairment

Interventions

DRUG

Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)

Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.

Trial Locations (2)

32809

Medical Facility, Orlando

33136

Medical Facility, Miami

Sponsors

Lead Sponsor

Spero Therapeutics

All Listed Sponsors

lead

Spero Therapeutics

INDUSTRY